Novartis FY2026 EPS Forecast Increased by Erste Group Bank

Novartis AG (NYSE:NVS) – Research analysts at Erste Group Bank upped their FY2026 earnings per share estimates for Novartis in a research note issued on Friday, June 5th. Erste Group Bank analyst H. Engel now anticipates that the company will earn $8.76 per share for the year, up from their prior estimate of $8.64. The consensus estimate for Novartis’ current full-year earnings is $8.82 per share. Erste Group Bank also issued estimates for Novartis’ FY2027 earnings at $9.76 EPS.

NVS has been the topic of several other research reports. TD Cowen restated a “hold” rating on shares of Novartis in a research note on Tuesday, February 17th. Argus raised shares of Novartis from a “hold” rating to a “buy” rating and set a $180.00 price objective for the company in a research report on Wednesday, March 11th. Sanford C. Bernstein upgraded Novartis to a “hold” rating in a research report on Thursday, March 19th. Morgan Stanley raised their price objective on Novartis from $143.00 to $170.00 and gave the stock an “overweight” rating in a research note on Thursday, March 26th. Finally, Weiss Ratings cut shares of Novartis from a “buy (a-)” rating to a “buy (b)” rating in a research note on Wednesday, April 29th. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $141.20.

Novartis Price Performance

Shares of NYSE NVS opened at $153.03 on Monday. The firm has a market cap of $292.00 billion, a P/E ratio of 21.92, a PEG ratio of 2.69 and a beta of 0.46. The company has a quick ratio of 0.65, a current ratio of 0.85 and a debt-to-equity ratio of 0.96. Novartis has a twelve month low of $112.34 and a twelve month high of $170.46. The company has a 50 day moving average of $149.47 and a 200 day moving average of $148.21.

Novartis (NYSE:NVS) last posted its quarterly earnings results on Monday, April 27th. The company reported $1.99 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.11 by ($0.12). The company had revenue of $13.52 billion during the quarter, compared to analysts’ expectations of $13.44 billion. Novartis had a return on equity of 38.82% and a net margin of 24.87%.Novartis’s revenue for the quarter was down .9% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.28 EPS.

Institutional Trading of Novartis

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Auto Owners Insurance Co increased its position in Novartis by 13,687.0% during the fourth quarter. Auto Owners Insurance Co now owns 4,628,296 shares of the company’s stock valued at $638,103,000 after acquiring an additional 4,594,726 shares during the last quarter. WCM Investment Management LLC bought a new position in shares of Novartis during the first quarter valued at approximately $220,004,000. Morgan Stanley grew its stake in shares of Novartis by 14.9% during the fourth quarter. Morgan Stanley now owns 8,876,906 shares of the company’s stock valued at $1,223,860,000 after buying an additional 1,148,033 shares during the last quarter. GQG Partners LLC increased its stake in Novartis by 39.6% in the fourth quarter. GQG Partners LLC now owns 3,158,122 shares of the company’s stock worth $435,414,000 after purchasing an additional 895,255 shares during the period. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in Novartis in the fourth quarter worth $108,638,000. Hedge funds and other institutional investors own 13.12% of the company’s stock.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.